ERCC1 and neoplasm: Thus, with the identification of both a BRCA2 mutation and ERCC1 negativity, this case clearly demonstrates the benefit of molecular profiling in optimising therapy for this rare tumour and avoiding aggressive protocols from which the patient was unlikely to derive benefit.